Lingvay I, et al. - In this 26-week, multicenter, double-blind trial, the researchers examined the efficacy and safety of once-daily semaglutide in comparison with once-daily liraglutide and placebo in patients with type 2 diabetes. Participants in the study were patients diagnosed with type 2 diabetes with HbA_1c 7.0–10.0% (53–86 mmol/mol) and treated with diet and exercise with or without metformin. According to the findings obtained, once-daily semaglutide at doses up to 0.3 mg/day resulted in greater reductions in HbA_1c compared with liraglutide or placebo. The most common adverse events (AEs) with semaglutide and liraglutide were gastrointestinal (GI) disorders.